TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36382108
Drug: ONC201 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (625 mg, orally administered, scaled by body weight)
Study: 36382109
Drug: Trotabresib 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trotabresib 15, 30, and 45 mg combined with TMZ in the adjuvant setting
Study: 36382109
Drug: Trotabresib 15
Normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trotabresib 15 and 30 mg combined with TMZ+RT in the concomitant setting
Study: 36382109
Drug: Trotabresib 30
Normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trotabresib 30 mg established as the recommended phase II dose (RP2D) in both settings
Study: 36382554
Drug: Atezolizumab in
Normalized name: atezolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab in combination with ado-trastuzumab emtansine
Study: 36382554
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with ado-trastuzumab emtansine
Study: 36383021
Drug: CoronaVac (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (inactivated vaccine)
Study: 36383294
Drug: BT595 (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT595 (10% Human Normal Immunoglobulin) administered at doses between 0.2 and 0.8 g/kg body weight for approximately 12 months at intervals of either 3 or 4 weeks
Study: 36384656
Drug: Insulin treated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treated diabetics
Study: 36385011
Drug: Interferon-lambda treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-lambda treatment
Study: 36385120
Drug: CYH33 1-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYH33 1-60 mg
Study: 36385136
Drug: Maximum daily
Normalized name: Ascorbic Acid/Biotin/Boron/Calcium/Chloride/Chromium/Copper/Cyanocobalamin/Folic Acid/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacin/Nickel/Pantothenic Acid/Phosphorus/Phytonadione/Potassium/Pyridoxine/Riboflavin/Selenium/Silicon Dioxide/Thiamine/Tin/Vanadium/Vitamin A/Vitamin D/Vitamin E/Zinc 50 MG-30 MCG-150 MCG-162 MG-72 MG-65 MCG-2 MG-6 MCG-400 MCG-150 MCG-19 MG-100 MG-3.5 MG-160 MCG-20 MG-5 MCG-10 MG-109 MG-25 MCG-80 MG-2 MG-1.7 MG-20 MCG-2 MG-1.5 MG-10 MCG-10 MCG-2500 IU-400 IU-30 IU-15 MG Oral Tablet [QUALITY CHOICE MAXIMUM DAILY MULTIVITAMIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum daily precipitation increase (10 cm)
Study: 36385136
Drug: Specific humidity
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific humidity increase (g/kg)
Study: 36385536
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events.
Study: 36385536
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib 4 mg weekly combined with short-course rituximab (4-week course added during month 7).
Study: 36386029
Drug: Surfactant (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (two or more doses)
Study: 36386029
Drug: Surfactant (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (one or less doses)
Study: 36386418
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol (Group P)
Study: 36386418
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with sevoflurane (Group S)
Study: 36388237
Drug: Optimized Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized Medical Treatment (OMT)
Study: 36389355
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (5 daily drops for 4 weeks)
Study: 36394153
Drug: PF-06939999 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.)
Study: 36394250
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Behavioral Therapy (MBCBT)
Study: 36394867
Drug: Avelumab 800
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg every 2 weeks and Talazoparib 1 mg once daily
Study: 36395084
Drug: Blue Light-Emitting
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue Light-Emitting Diode Therapy
Study: 36395401
Drug: Ziv-aflibercept 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept 4 mg/kg intravenously on day 1 and 15 of a 28-day cycle (reduced to 2 mg/kg due to hypertension-related events)
Study: 36396665
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib (5 cycles of 4-week treatment)
Study: 36396665
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib
Study: 36398439
Drug: Entinostat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (5 mg/week) plus exemestane (25 mg/day)
Study: 36399068
Drug: JDQ443, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS
Study: 36399178
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) - regular cohort (3 initial monthly injections followed by injections every 2 months)
Study: 36399178
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) - irregular cohort with initial monthly injections
Study: 36399178
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) - irregular cohort without initial monthly injections
Study: 36400069
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg twice daily or 320 mg once daily
Study: 36400106
Drug: Zanidatamab 20
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab 20 mg/kg every 2 weeks (Part 2)
Study: 36401732
Drug: GDC-0810 100-800
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0810 100-800 mg once daily or 300-400 mg twice daily
Study: 36401732
Drug: GDC-0810 600
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0810 600 mg QD taken with food
Study: 36401886
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose, B12-vitamin, and folic acid administered 1 day before surgery.
Study: 36402009
Drug: 25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/day increment of dietary protein intake
Study: 36402146
Drug: Ponatinib 30
Normalized name: PONATinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 30 mg orally and continuous intravenous blinatumomab 28 μg over 24 h for 28 days each cycle, followed by ponatinib monotherapy.
Study: 36402744
Drug: Novel radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel radiation therapy schedule (3.96 Gy × 7 followed by 1.0 Gy × 9)
Study: 36402744
Drug: Novel radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel radiation therapy schedule
Study: 36402752
Drug: PD-L1-targeting chimeric
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-L1-targeting chimeric switch receptor (PD-L1.BB CSR) modified CAR-T cells
Study: 36403075
Drug: Drug quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug quality
Study: 36403579
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg) plus nivolumab (3 mg/kg) intravenously starting 30-60 days after autologous HSCT for up to 8 cycles.
Study: 36403700
Drug: Bivalent SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C
Study: 36404469
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment, specific dosage and duration not mentioned
Study: 36404730
Drug: Lifestyle program;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle program; details on dosage and duration not available
Study: 36405821
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of corticosteroid therapy (Group A)
Study: 36405821
Drug: 12-14 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-14 weeks of standard therapy (Group B)
Study: 36406817
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate 325 mg twice daily for 12 months
Study: 36408923
Drug: Thermal ablation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal ablation treatment
Study: 36409226
Drug: Work-related group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-related group cognitive behavioral therapy plus vocational services (WCBT+VSAU)
Study: 36409282
Drug: Low-dose extended
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose extended half-life (EHL) FVIII prophylaxis with PK-based adjustment
Study: 36409282
Drug: Low-dose standard
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose standard half-life (SHL) FVIII prophylaxis
Study: 36409354
Drug: Maximal tolerable
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal tolerable doses of evidence-based medications
Study: 36409773
Drug: Therapeutic responses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic responses to available and new compounds against Trypanosoma cruzi infection.
Study: 36410797
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability biofeedback (HRV-B) intervention using a Polar chest strap device linked to the Elite HRV phone application for 4 weeks, with two 10-minute sessions daily for at least 5 days a week.
Study: 36411033
Drug: Gepotidacin 3000
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 3000 mg oral doses administered 10-12 hours apart
Study: 36411267
Drug: AZD7442 (tixagevimab/cilgavimab)
Normalized name: tixagevimab
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (tixagevimab/cilgavimab) 300 mg (1.5 mL intramuscular injection)
Study: 36412229
Drug: Man Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Man Therapy (MT)
Study: 36412798
Drug: Peripheral Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral Intravenous Catheters (PIVC)
Study: 36413205
Drug: Weekly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physical activity levels
Study: 36413221
Drug: Blended care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended care (interactive e-learning program based on cognitive behavioral therapy for insomnia)
Study: 36413390
Drug: App-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app for 12 weeks.
Study: 36413390
Drug: App-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app.
Study: 36413418
Drug: Tralesinidase alfa
Normalized name: Tralesinidase alfa
DrugBank: Tralesinidase alfa (DB17657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralesinidase alfa (300 mg)
Study: 36415604
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of SARS-CoV-2 vaccine (vaccine group)
Study: 36415604
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of SARS-CoV-2 vaccine (control group)
Study: 36415604
Drug: Hybrid immunity
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid immunity (three vaccine doses followed by COVID-19)
Study: 36415604
Drug: Three and
Normalized name: ZINC OXIDE 150 mg in 1 mL TOPICAL CREAM [Slip Tint Broad Spectrum SPF 35 Sunscreen Tinted Moisturizer Shade Three and Half]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three and four doses of SARS-CoV-2 vaccine (both groups)
Study: 36416136
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors (PCSK9i)
Study: 36416880
Drug: Cancer-specific meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer-specific meditation app prototype used daily (≥70 minutes per week) for 4 weeks
Study: 36416880
Drug: Weekly and
Normalized name: Ezy Dose Weekly And Portable Pill Planner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly and poststudy questionnaires
Study: 36417764
Drug: Wide-diameter bone-anchored
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-diameter bone-anchored hearing implant (loaded at 3 weeks after surgery)
Study: 36417764
Drug: Wide-diameter bone-anchored
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Study: 36417764
Drug: Previous-generation small-diameter
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous-generation small-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Study: 36417764
Drug: Wide-diameter bone-anchored
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-diameter bone-anchored hearing implant
Study: 36418119
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (protocol-specified antidepressants)
Study: 36418127
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask sampling with polyvinyl alcohol test strips for 2 hours daily over at least 7 days.
Study: 36418127
Drug: Self-administered nasal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered nasal swabs and optional finger prick blood samples.
Study: 36418966
Drug: suPAR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR ≥ 8.0 ng/mL in patients with infection
Study: 36418966
Drug: suPAR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR ≥ 8.0 ng/mL in patients without infection
Study: 36418966
Drug: suPAR ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR ≥ 8.0 ng/mL in patients who developed sepsis
Study: 36418965
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (various classes including penicillins, fluoroquinolones, and macrolides)
Study: 36418965
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid and levofloxacin
Study: 36419331
Drug: Empirical prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical prophylaxis with oral ciprofloxacin (control group)
Study: 36419530
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day gabapentin
Study: 36419530
Drug: 1,800 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg/day gabapentin
Study: 36424628
Drug: Conteltinib (CT-707)
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conteltinib (CT-707) at doses of 50 to 800 mg QD
Study: 36426287
Drug: Nivolumab-Ipilimumab combination
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab-Ipilimumab combination (NI)
Study: 36426808
Drug: Nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks followed by dose-dense epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) for four 2-week cycles
Study: 36426808
Drug: Nab-paclitaxel followed
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel followed by dose-dense EC
Study: 36427020
Drug: Ulixertinib 600
Normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulixertinib 600 mg PO BID (de-escalated to 450 mg BID) plus gemcitabine and nab-paclitaxel (GnP)
Study: 36427162
Drug: Caplacizumab 10
Normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Caplacizumab 10 mg administered daily during plasma exchange and for 30 days afterward, in combination with immunosuppressive treatment
Study: 36427183
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment
Study: 36427183
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with endocrine therapy
Study: 36427183
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment effectiveness
Study: 36427229
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for NSTI (including surgery and broad-spectrum antibiotics)
Study: 36427234
Drug: Adapted Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Physical Activity (APA) along with chemotherapy, supervised by a qualified kinesiologist, including endurance and resistance training at moderate intensity 3 times a week for 6 months.
Study: 36427234
Drug: Adapted Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted Physical Activity (APA) along with chemotherapy.
Study: 36427234
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (control group).
Study: 36427645
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes, delivering 6750 cGy to the prostate and 4500 cGy to the pelvic lymph nodes in 25 daily fractions.
Study: 36427645
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes.
Study: 37226504
Drug: SCB-2019 vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 vaccine
Study: 36433829
Drug: isatuximab 20
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: isatuximab 20 mg/kg QW/Q2W
Study: 36434392
Drug: Combination hypofractionated
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1)
Study: 36434554
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day) and Avelumab (800 mg on days 1 and 15)
Study: 36435266
Drug: BAY2586116 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2586116 (160 μg) nasal spray
Study: 36435266
Drug: BAY2586116 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2586116 (3 μg) nasal drops
Study: 36435266
Drug: BAY2586116 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2586116 (30 μg) nasal drops
Study: 36435928
Drug: Neural crest
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural crest tumour treatment
Study: 36435949
Drug: New formula
Normalized name: Correct (New Formula)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formula for calculating Lp(a)-C from molar measurement of Lp(a) (Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL)
Study: 36436013
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP)
Study: 36436128
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of endocrine therapy (ET)
Study: 36436128
Drug: Non-persistence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-persistence of endocrine therapy (ET)
Study: 36436128
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and symptom burden
Study: 36436320
Drug: Fampridine treatment
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fampridine treatment for 14 days
Study: 36436423
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NET) with genomic testing using 70-gene and 80-gene signatures
Study: 36436615
Drug: Mean heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean heart dose ≥10 Gy
Study: 36436615
Drug: Mean heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean heart dose <10 Gy